We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Kromek Group Plc | LSE:KMK | London | Ordinary Share | GB00BD7V5D43 | ORD 1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -0.20 | -3.77% | 5.10 | 904,632 | 11:28:39 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 5.00 | 5.20 | 5.30 | 5.10 | 5.30 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Miscellaneous Metal Ores,nec | 19.4M | -3.29M | -0.0051 | -10.00 | 34M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:33:13 | O | 500,000 | 4.90 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 13/12/2024 | 12:20 | UK RNS | Kromek Group PLC Result of AGM |
| 18/11/2024 | 07:00 | UK RNS | Kromek Group PLC Notice of AGM and Publication of Annual Report |
| 28/10/2024 | 12:23 | ALNC |  Kromek narrows annual loss as geopolitical insecurity drives demand |
| 28/10/2024 | 07:01 | UK RNS | Kromek Group PLC Final Results and Publication of Annual Report |
| 28/10/2024 | 07:00 | UK RNS | Kromek Group PLC Financing Update |
| 30/9/2024 | 06:00 | UK RNS | Kromek Group PLC Update on Full Year Results |
| 23/9/2024 | 06:00 | UK RNS | Kromek Group PLC Kromek selected for UK Government Framework |
| 16/9/2024 | 10:46 | ALNC | Kromek wins GBP2 million contract with UK Ministry of Defence |
| 16/9/2024 | 06:00 | UK RNS | Kromek Group PLC Kromek awarded £2.0m contract from UK MOD |
| 21/8/2024 | 09:14 | UK RNS | Kromek Group PLC Holding(s) in Company |
Kromek (KMK) Share Charts1 Year Kromek Chart |
|
1 Month Kromek Chart |
Intraday Kromek Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 15/12/2024 | 17:47 | Kromek Group PLC | 7,190 |
| 05/1/2022 | 09:19 | Kromek Group (KMK) - Overvalued AIM mugging | 182 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2024-12-20 16:33:14 | 4.90 | 500,000 | 24,500.00 | O |
| 2024-12-20 16:11:32 | 5.03 | 8,496 | 426.92 | O |
| Top Posts |
|---|
Posted at 21/12/2024 08:20 by Kromek Daily Update Kromek Group Plc is listed in the Miscellaneous Metal Ores,nec sector of the London Stock Exchange with ticker KMK. The last closing price for Kromek was 5.30p.Kromek currently has 641,550,000 shares in issue. The market capitalisation of Kromek is £32,719,050. Kromek has a price to earnings ratio (PE ratio) of -10.00. This morning KMK shares opened at 5.30p |
Posted at 20/11/2024 17:52 by yusuf77 off topic-znt ready to take off not many shares only 38.69m shares in issue a share to get inearly 2 director buys last week ready to blow deal done |
Posted at 29/10/2024 10:14 by estienne Well here's a bit of itFull-year revenue up 12 per cent to £19.4mn Cash profit of £3.1mn well ahead of £1.2mn market estimate Underlying operating loss slashed from £6mn to £1.4mn Forecast positive cash flow in 2024/25 financial year New secured loan provides additional working capital Sedgefield-based Kromek (KMK:5.65p), a radiation detection technology group, materially outperformed house broker Cavendish’s full-year cash profit estimate even though revenue of £19.4mn was £1.6mn shy of expectations due to timing issues. Buoyed by the contribution from its higher-margin chemical, biological, radiological and nuclear (CBRN) detection business (revenue up 16 per cent to £7.1mn) and research and development activities (revenue up a fifth to £3mn), group gross margin of 55.2 per cent was seven percentage points higher than analysts had predicted and meant that gross profit increased 20 per cent to £10.7mn, well ahead of £10mn forecast. A focus on cost control contributed to the result, too. Total operating expenses decreased by £2.6mn to £12.6mn, or £1.3mn lower than Cavendish had predicted, hence a £2mn outperformance at the cash profit level and material reduction in operating loss. |
Posted at 29/10/2024 08:42 by ivyhedge a few words of wisdom in the IC magazine. nothing much has changed, like most companies unless making a pile of ready cash they need a banking facility to draw on. Fundamentals are good as far as I can see. bought a few more while price dropped. |
Posted at 28/10/2024 11:09 by earwacks Cash balance has always been a touchy subject with KmK unsurprisingly. Well they came up with half a million. Such a hard one to judge. They definitely have reasonably good growth after some sticky patches. However as fast as the growth accelerates so does dilution and debt. At some point would hope the balance would tip where they manage their first year without the need for more cash injection. As frustrating as this company has been, it might be just beginning to get there. Question is, does it need another year or will 2025 be the one for kmk. I suspect it will take at least 1 more year. Research tree are positive and even Stickopedia dont rate this the worst share ever now. I’m tempted again by the possible reward, but there are equally good investment cases with so many in the same boat.it just takes one hiccup. Its a struggle! |
Posted at 30/7/2024 11:18 by ark87 andrew97 - Literally what every investor here been hoping for since the IPO 11 years ago. share price was 49 back then btw!! With KMK history usually repeats itself. So right now they desperate for some hype job to get anonther placing off. What ever happened to those game changing covid detectors? |
Posted at 05/2/2024 11:30 by brynos KROMEK GROUP PLCReleased 10:17:36 05 February 2024 RNS Number : 0345C Kromek Group PLC 05 February 2024 5 February 2024 Kromek Group plc ("Kromek" or the "Company" or the "Group") Conversion of £1.5m of Convertible Loan Notes Kromek Group plc (AIM: KMK), a leading developer of radiation and bio-detection technology solutions for the advanced imaging and CBRN detection segments, announces that two holders of the convertible loan notes ("Loan Notes") issued in August 2022 have elected to convert them into new ordinary shares of 1 penny each in the Company ("Ordinary Shares") at conversion prices of 6.3 pence and 7.1 pence, per Ordinary Share. Including accrued interest, the Loan Note holders are converting £1,509,211 of debt into 23,639,520 new Ordinary Shares and accordingly these new Ordinary Shares have been issued and allotted by the board. The issue prices of 6.3 and 7.1 pence per new Ordinary Share represent the closing price of the Company's Ordinary Shares on AIM on 31 January 2024 and 2 February 2024, respectively, being the repayment date of the convertible loan note facilities. Application has been made for the 23,639,520 Ordinary Shares to be admitted to trading on AIM and dealings are expected to commence on or around 8.00 a.m. on 9 February 2024 ("Admission"). The new Ordinary Shares will rank pari passu with the existing shares of the Company. Following Admission, the Company's issued share capital will consist of 623,886,340 Ordinary Shares, none of which are held in treasury. Accordingly, the figure of 623,886,340 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules. |
Posted at 08/1/2024 20:31 by jaknife The recent boom in the number of shares is because of a convertible loan note. The last share conversion under the note was announced here:All is not what it seems and the directors have been deliberately deceptive on two levels. 1. Fixed Conversion Price The original RNS that announced the terms of the convertible is here: The conversion terms are described as: "The Loan Notes have a term of 18 months (with the Company having the option to extend the majority of the loan notes by three months), are senior in ranking and unsecured. The Loan Notes are convertible at investors option into ordinary shares in the capital of the Company ("Ordinary Shares") at 15 pence per Ordinary Share, representing a 30% premium to the mid-price of the Company's share price at close of business on 04 August 2022. The Loan Notes carry a coupon of 8% per annum and have a conversion date of 31 January 2024." And so you would be forgiven if you thought that the loan was convertible at 15p a share - it is not! The RNS then goes onto note: "The Loan Note holders have the right to elect to be repaid in whole or in part in Ordinary Shares at the lower of the closing mid-market price on the repayment date, and 15 pence per share." The reality of the wording is that this boils down to: "The Loan Note holders have the right to elect to be repaid in Ordinary Shares issued at the closing mid-market price on the repayment date." 2. Interest But there is a second more important deliberate deception that the directors are executing, which relates to the terms on which the interest on the loan is converted to shares. Specifically the directors have not disclosed in any formal RNS what the terms of conversion are for the interest element of the bond. It's not easy to work out what those terms are but we can work out that the terms are incredibly onerous. Going back to the recent conversion notice: it tells us that: ”Kromek … has issued and allotted 7,830,628 new ordinary shares in the Company ("Shares") at a conversion price of 5.11 pence per Share in order to settle the exercise of convertible loan notes and repayment of interest to certain convertible loan note holders … The Partial Conversion reduces the amount owing on the convertible notes by £261,000, with £2,579,000 remaining.” But if you do the simple calculation of £261,000 / 7,830,628 then you get to a conversion price of 3.33p!!! The explanation is that the RNS disclosure above only relates to principal and doesn’t include interest. Hence 5,107,632 shares have been issued at a price of 5.11p a share to repay the principal of £261,000 ( 5,107,632 shares x 5.11p = £261,000 ) and then a further 2,722,996 shares have been issued ( 7,830,628 - 5,107,632 ) to pay an undisclosed amount of interest at an undisclosed conversion price. Having different conversion terms for the principal and interest is a new trend with convertible loans, you can find similar convertible loans with both COPL and SOU that have different conversion terms between principal and interest. There’s no benefit to having these unusual terms other than to deceive shareholders into thinking that the deal is better than it actually is. JakNife |
Posted at 02/1/2024 12:22 by jaknife This is the article. Perhaps it's my settings but I can't see any reader comments.==================== Kromek boss ‘might not have listed technology company on Aim’ Arnab Basu joins other technology bosses ‘frustrated Katie Prescott, Technology Business Editor Tuesday December 26 2023, 12.01am GMT, The Times Arnab Basu, the chief executive of Kromek, argues that technology businesses that require time and investment to grow are often ignored by UK investors in favour of short-term successes The boss of Kromek has said that with hindsight he might not have listed the scanning technology business on London’s junior stock market, adding his voice to those of other British technology chief executives who complain that the City lacks understanding of the sector. The share price of the Co Durham-based company, which designs and makes high-specification materials for security and medical imaging, has fallen by more than 90 per cent since it was listed on Aim in 2013, despite Kromek increasing its revenue and market share. Arnab Basu said it was “frustrating that the company’s value isn’t recognised”. The business, which celebrated its 20th anniversary this year, made £17 million of revenue in 2022, a 44 per cent rise from the year before. However, it has yet to make a profit, suffering an adjusted pre-tax loss of £7 million in 2023, down from £7.8 million the year before. About a third of its revenue is from the United States and a fifth from Britain. Kromek is covered by only one firm of City analysts — Cavendish, part of the finnCap Group. In July, after the company’s full-year results, Mark Brewer, finnCap’s director of research, wrote: “As the only independent supplier at scale of CZT [a semiconductor] for imaging systems, we believe there is substantial strategic value in Kromek that is not reflected in the current price.” Another London technology analyst, who does not follow the stock, said: “The low end of the Aim market capitalisation spectrum can be a trap in terms of low valuations. The company capitalises a lot of development costs and has been cashflow-negative for the past two years; improving profitability and turning cash-positive will be keys to getting a higher valuation.” Reflecting on its ten years as a public company, Basu, 50, said: “We have had a difficult time in the market, where the business has grown continuously but the value recognition has declined continuously. When you’re talking to retail investors, it must be very challenging for them to really understand a small, complex business. The relationship we had with private investors was much more interactive.” He argued that technology businesses that required time and investment to grow were often ignored in favour of short-term successes. “Hardware tech is still rare in the UK. And I think if you’re not in certain segments, understanding and the pool of investors within that is reasonably limited, which creates a pressure. Kromek’s story is shared by many compatriots in the tech market.” Basu moved to Newcastle from India for his degree and stayed in the city, spinning out his doctorate from Durham University into a business that supplies medical companies, airports and security services worldwide. Kromek developed a semiconductor technology and manufacturing process that goes into a range of applications, including creating Europe’s first liquid explosive detection system, and has won its first contract with the European Space Agency. Based in Sedgefield, the company employs 150 people with offices and manufacturing facilities in Pennsylvania and California. It supplies the US Department of Homeland Security and works with Darpa, the US defence agency, producing a portfolio of products for the military in radiation detection. Among the products in the pipeline, it is developing an airborne pathogen-testing system. The company works on detection in oncology, Alzheimer’s and cardiac processes and in the analysis of airborne diseases. Another area is radiation detection and Basu said it was looking at early warnings of biological or chemical weapons being used in public areas from cities to stadiums. |
Posted at 09/5/2023 19:21 by aqc888 For some context;Pivotal year unfolding for Kromek - 18/1/22 Share price 14.5p Winners in an uncertain world - 16/5/22 Share price 9.7p Kromek’s record sales visibility is materially undervalued - 2/8/22 Share price 9.5p A biological detection winner - 11/22 Share price 8.75p This stock is about to turn world-leading technology into profit - 2/23 Analysts think this stock's share price will quadruple - 4/23 Share price 6.85p Buy into Kromek's £7.5mn open offer of new shares - today Share price 5p …. It goes back way further when share price was way way higher… “Don't worry about Kromek's revenue fall“ - 1/2019 Share price 26p |
Posted at 10/8/2022 02:36 by ark87 The shareprice was down until IC tipped it (again). Unfortunately as you can see from KMK share price performance since inception (51p to to 14p over 9 years) will be short lived unless some game changing news is on horizon which at this point seems doubtful. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
